News | Vitalis

VTS-72 aims to be the next generation oral fumarate therapy, that may hold potential as a treatment for MS with fewer side effects and other clinical benefits for these patients.

Aiming to submit NDA in 2020-2021.

VTS-72 aims to be the next generation oral fumarate therapy, that may hold potential as a treatment for MS with fewer side effects and other clinical benefits for these patients.

Aiming to submit NDA in 2020-2021.

VTS-K: Ketamine + VTS Aspirin for Postoperative Pain

VTS-K: Ketamine + VTS Aspirin for Postoperative Pain

Vitalis

Media

ER Doctor Aims for Patient Centered Breakthrough: A Ketamine That Works Orally

Ketamine News

January 28, 2021

VTS-Aspirin Wins Orphan Status in Combination With Fumarates for Flush in MS

NeurologyLive

April 28, 2020

Novel Aspirin Formulation May Address Bothersome MS Symptoms, Treatment Side Effects

NeurologyLive

January 10, 2020

Vitalis Announces Plans for Low-Flush Formulation Fumarate VTS-72 In Multiple Sclerosis

NeurologyLive

October 24, 2019

Potential RRMS Fumarate Treatment Free of ‘Flush’ Effect to Enter Trial in 2020, Vitalis Says

MS News Today

October 24, 2019

BioWorld Today - October 23, 2019: Other news to note

BioWorld

subscription required to view full article

October 23, 2019

A new company enters the Tecfidera fight, offering to kill two birds

ENDPOINTSNEWS

October 22, 2019

Vitalis Plans to Launch Phase 3 Trial Testing VTS-72 as Treatment for RRMS-related Flushing

MS News Today

January 10, 2020

VTS-Aspirin Combos to Ease Flush in RRMS Named Orphan Drug by FDA

MS News Today

April 23, 2020

H. C. Wainwright 22nd Annual Global Investment Conference

Wall Street Webcasting

September 16, 2020

Pilot Study Launched of Ketamine Tablet as Pain Reliever

Pain News Network

January 20, 2021